News | Structural Heart Occluders | February 13, 2019

Le Bonheur Children's Hospital Implants First Abbott Amplatzer Piccolo Occluder

Two-week-old patient is world's first to receive transcatheter device for patent ductus arteriosus (PDA) after recent FDA approval

Le Bonheur Children's Hospital Implants First Abbott Amplatzer Piccolo Occluder

February 13, 2019 — Le Bonheur Children's Hospital cardiologists in Memphis, Tenn., implanted the Amplatzer Piccolo Occluder, the world's first commercially-approved medical device for transcatheter patent ductus arteriosus (PDA) closure in babies weighing as little as two pounds. The self-expanding, wire mesh device developed by Abbott is inserted through a small incision in the leg and guided through vessels to the heart, where it is placed to seal the opening of the heart.

Shyam Sathanandam, M.D., medical director of Le Bonheur's Interventional Cardiac Imaging and Interventional Catheterization Laboratory, helped pioneer the transcatheter closure before joining an eight-site U.S. Food and Drug Administration (FDA)-approved trial for the Amplatzer Piccolo Occluder used in the closure. Le Bonheur enrolled more neonates than any other center in the study.

Shyam and his team closed the PDA in the first patient post-approval, a two-week-old baby girl, born at 28 weeks and weighing 1 kilogram.

Abbott's Piccolo device is smaller than a pea and now offers hope to premature infants and newborns who need corrective treatment, and who may be non-responsive to medical management and high risk to undergo corrective surgery.

Approximately 60,000 premature babies in the U.S. are born each year with a very low birth weight, and nearly 12,000 (one out of five) of these have a significant PDA which will require urgent treatment for the baby to survive.

For more information: www.abbott.com

Related Content

News | Cath Lab

May 31, 2022 — Innovative Health, LLC, a specialty cardiology reprocessor, announced that the company has received ...

Home May 31, 2022
Home
News | Cath Lab

May 26, 2022 — The U.S. Food and Drug Administration (FDA) has recalled the Dragonfly OpStar Imaging Catheter, and has ...

Home May 26, 2022
Home
News | Cath Lab
April 25, 2022 – NewYork-Presbyterian Hudson Valley Hospital celebrated the launch of its interventional cardiology ...
Home April 25, 2022
Home
News | Cath Lab
April 18, 2022 – Royal Philips and Oulu University Hospital (Finland) have announced a strategic 10-year partnership ...
Home April 18, 2022
Home
News | Cath Lab
February 16, 2022 – Fremont Bank Foundation recently donated $750,000 to its community partner, St. Rose Hospital ...
Home February 16, 2022
Home
News | Cath Lab
February 14, 2022 — A collaborative effort between The Valley Heart and Vascular Institute’s cardiology team ...
Home February 14, 2022
Home
Sponsored Content | Videos | Cath Lab

Advancements in analytics and data visualizations are helping to streamline operations and improve productivity at cath ...

Home January 13, 2022
Home
News | Cath Lab

January 4, 2022 — The U.S. Food and Drug Administration (FDA) has authorized marketing of the first laser-based device ...

Home January 04, 2022
Home
News | Cath Lab

December 14, 2021 — RSIP Vision, a medical imaging company applying advanced artificial intelligence (AI) and computer ...

Home December 14, 2021
Home
Feature | Cath Lab

November 15, 2021 — RealView Imaging Ltd. recently received FDA 510(k) clearance for its Holoscope-i holographic system ...

Home November 15, 2021
Home
Subscribe Now